History of acute coronary syndromes, including myocardial infarction, coronary artery bypass graft, unstable angina, coronary angioplasty or stenting within past  weeks.
Acute coronary syndrome within  months prior to starting treatment
Recent (within  months) history of second degree (Type II) or third degree atrioventricular (AV) block cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting, or bypass grafting; Class II, III, or IV heart failure, or symptomatic pericarditis.
Acute coronary syndrome
Cardiac abnormalities:\r\n* Mean QTc interval >=  msec at screening\r\n* Acute coronary syndrome (ACS)/acute myocardial infarction (AMI) within  weeks prior to screening\r\n* Percutaneous coronary intervention (PCI)/percutaneous transluminal coronary angioplasty (PTCA) within  weeks prior to screening\r\n* Symptomatic heart failure  New York Heart Association (NYHA) class >= II symptoms
Clinically significant, uncontrolled heart disease and/or recent events including any of the following:\r\n* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting\r\n* Coronary angioplasty, or stenting) or symptomatic pericarditis within  months prior to screening\r\n* History of documented congestive heart failure (New York Heart Association functional classification III-IV)\r\n* Documented cardiomyopathy\r\n* Patient has a left ventricular ejection fraction < % as determined by multigated acquisition (MUGA) scan or echocardiography (ECHO) (MUGA and ECHO are not required prior to enrollment)
History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or stent placement within  months prior to study drug dosing
Any other significant medical condition not under control, including any acute coronary syndrome within the past  months
Significant cardiovascular risk including, but not limited to, recent (within  weeks) coronary stenting or myocardial infarction within  months
History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within  months prior to registration.
Inpatient admission to a hospital for unstable angina or myocardial infarction within the last  months prior to first dose or percutaneous cardiac intervention with recent stent within  months or coronary artery bypass grafting within  months
Myocardial infarction, stroke, coronary artery bypass surgery, coronary stent, or unstable angina within one year are excluded; Note: A subject may enroll in the study and have a start date set in the near future in a way that meets the timelines for exclusion items by the treatment start date
Significant cardiovascular risk including, but not limited to, recent (within  weeks) coronary stenting or myocardial infarction within  months
history of acute coronary syndromes (including unstable angina)
Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\r\n* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <  months prior to screening\r\n* Symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
Patients experiencing a cardiac events (acute coronary syndrome, myocardial infarction, or ischemia) within the  months prior to accrual
Has significant cardiac conduction abnormalities and/ or pacemaker or any of the following criteria:\r\n* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft [CABG], coronary angioplasty, or stenting) <  months prior to screening\r\n* Symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening\r\n* Uncontrolled arterial hypertension, defined as blood pressure (BP) > / mmHg (average of  consecutive readings)
Patients have clinically significant cardiovascular disease, including any of the following: \r\n* History of acute coronary syndrome including myocardial infarction, unstable angina, coronary artery bypass graft (CABG), coronary angioplasty or stenting <  months prior to screening\r\n* Symptomatic chronic heart failure (New York Heart Association criteria, class II-IV)\r\n* Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT)
Patient do not have adequate cardiac function defined as:\r\n* Left ventricular ejection fraction (LVEF) =< % as determined by a multigated acquisition (MUGA) scan or echocardiogram\r\n* Corrected QT (QTc) interval >=  ms\r\n* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting [CABG], coronary angioplasty, or stenting) <  months prior to screening\r\n* Symptomatic chronic heart failure; evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening
History or evidence of cardiovascular (CV) risk including any of the following: a) Recent (within the past  months) history of serious uncontrolled cardiac arrhythmia or clinically significant ECG abnormalities including second degree (Type II) or third degree atrioventricular block. b) Cardiomyopathy, myocardial infarction, acute coronary syndromes (including unstable angina pectoris), coronary angioplasty, stenting, or bypass grafting within the past  months before enrollment. c) Congestive heart failure (Class II, III, or IV) as defined by the New York Heart Association (NYHA) functional classification system. d) Recent (within the past  months) history of symptomatic pericarditis.
Acute coronary syndrome, or any form of coronary revascularization procedure (including coronary artery bypass grafting [CABG]), within  months of screening.
History of myocardial infarction, acute coronary syndromes or coronary angioplasty/stenting/bypass grafting within the past  months.
History of or current coronary artery disease, myocardial infarction, angina pectoris, angioplasty or coronary bypass surgery
Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following within  months of enrollment: myocardial infarction, unstable angina, coronary artery bypass graft (CABG), coronary angioplasty, or stenting, symptomatic chronic heart failure, clinically significant cardiac arrhythmias and/or conduction (except atrial fibrillation and paroxysmal supraventricular tachycardia)
History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within  months prior to enrollment
History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass graft, coronary angioplasty, or stenting) <  months prior to screening
Impaired cardiovascular function or clinically specific cardiovascular disease including any of the following:\r\n* History of acute coronary syndromes (including myocardial infarction unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) =<  months; OR\r\n* Symptomatic chronic heart failure history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality <  months prior to screening; except atrial fibrillation and paroxysmal supraventricular tachycardia
Patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis
Patients with a history of coronary artery bypass grafting or angioplasty will receive a cardiology evaluation and be considered on a case-by-case basis
Subject has a high cardiovascular risk, including, but not limited to, recent coronary stenting or myocardial infarction in the past year.
History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) or symptomatic pericarditis within  months prior to screening
Patients have clinically significant cardiovascular disease, including any of the following \r\n* Any history of acute coronary syndrome including myocardial infarction, stable or unstable angina, coronary artery bypass grafting (CABG), coronary angioplasty or stenting, or known obstructive coronary artery disease\r\n* Symptomatic chronic heart failure (New York Heart Association criteria, class II-IV) \r\n* Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT)
History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within  months prior to enrollment.
History or evidence of cardiovascular risk including any of the following -- History of acute coronary syndromes (including myocardial infarction and angina), coronary angioplasty, or stenting within  months prior to enrollment. Additional Exclusion Criteria for Part E
History or evidence of cardiac risk, including:\r\n* Corrected QT interval on screening electrocardiogram (ECG) >  msec\r\n* Left ventricular ejection fraction (LVEF) < %\r\n* Clinically significant uncontrolled arrhythmias or arrhythmia requiring treatment with the exceptions of atrial fibrillation and paroxysmal supraventricular tachycardia\r\n* History of acute coronary syndromes within  months prior to the first dose of study therapy (including myocardial infarction and unstable angina, coronary artery bypass graft, angioplasty, or stenting)
Patients have clinically significant cardiovascular disease, including any of the following:\r\n* History of acute coronary syndrome including myocardial infarction, unstable angina, coronary artery bypass surgery (CABG), coronary angioplasty or stenting <  months prior to screening\r\n* Symptomatic chronic heart failure (New York Heart Association Criteria, class II-IV)\r\n* Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening except atrial fibrillation (AF) and paroxysmal supraventricular tachycardia (PSVT)
History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, and/or stenting up to  weeks before Cycle , Day
Stroke, transient ischemic attack, arterial embolism, percutaneous transluminal coronary angioplasty (PTCA), or coronary artery bypass grafting (CABG) within the past  months
History of acute coronary syndromes (specifically, myocardial infarction and unstable angina), severe/unstable angina, coronary angioplasty, or stenting within  months prior to the initiation of therapy on this protocol
History of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty and/or coronary artery stenting within the past  months
History of acute coronary syndromes (including myocardial infarction and unstable angina), coronary angioplasty, or stenting within  months prior to study enrollment
Any other significant medical condition not under control, including any acute coronary syndrome within the past  months
Known myocardial infarction, severe/unstable angina, percutaneous transluminal coronary angioplasty/stenting (PTCA), or coronary artery bypass graft (CABG) within  month of the first dose of the study treatment
Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\r\n* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting [CABG], coronary angioplasty, or stenting) <  months prior to screening\r\n* Symptomatic chronic heart failure\r\n* Evidence of clinically significant cardiac arrhythmias and/or conduction abnormalities <  months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
High cardiovascular risk, including but not limited to, recent coronary stenting or myocardial infarction in the past year
Myocardial infarction, unstable angina, coronary artery bypass graft, coronary artery angioplasty or stent placement within  months before scheduled dosing day ;
Active coronary artery disease, defined as myocardial infarction, unstable angina, coronary bypass graft, or stenting within  months prior to study entry
A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within  months prior to randomization
History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting [CABG], coronary angioplasty, or stenting) <  months prior to screening
A history of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty, or stenting within  months prior to randomization
Coronary angioplasty or stenting within the past  weeks
Recent acute coronary syndrome (ACS)/acute myocardial infarction (AMI)  defined as within  weeks prior to screening
Recent percutaneous coronary intervention (PCI)/percutaneous transluminal coronary angioplasty (PTCA)  defined as within  weeks prior to screening
A history (within  months prior to first dose of study treatment) of acute coronary syndromes (including myocardial infarction or unstable angina), coronary angioplasty
History of acute coronary syndromes.
History or evidence of cardiovascular risk including any of the following: Clinically significant electrocardiogram abnormalities including second degree (Type II) or third degree atrioventricular block; history of myocardial infarction, acute coronary syndromes (including unstable angina), coronary angioplasty, stenting, or bypass grafting within the past  months prior to enrolment, Class III or IV heart failure as defined by the New York Heart Association functional classification system, LVEF below %; known cardiac metastases
History of acute coronary syndromes (including unstable angina), coronary angioplasty, or stenting within the past  weeks.
Acute coronary syndrome
Impaired cardiovascular function or clinically significant cardiovascular diseases, including any of the following:\r\n* History of acute coronary syndromes (including myocardial infarction, unstable angina, coronary artery bypass grafting, coronary angioplasty, or stenting) <  months prior to screening,\r\n* Symptomatic chronic heart failure, history or current evidence of clinically significant cardiac arrhythmia and/or conduction abnormality <  months prior to screening except atrial fibrillation and paroxysmal supraventricular tachycardia
No unstable angina, myocardial infarction, or coronary angioplasty within the past  months or an untreated cardiac dysrhythmia
Myocardial infarction, acute coronary syndrome, revascularization surgery, or stroke within  months
Acute coronary event within the past month
Acute coronary (e.g. myocardial infarction) or vascular event within the last year as well as uncontrolled coronary heart disease (e.g. progressive angina)
Individuals with history of myocardial infarction, stroke, coronary-artery bypass draft, invasive coronary revascularization in the preceding  years
Patients who have experienced an acute coronary syndrome or angina in the past  months
Patients who have undergone coronary artery bypass grafting (CABG) or coronary stenting in the past  years
Significant cardiovascular risk including, but not limited to, recent (within  days) coronary stenting or myocardial infarction within  months
Acute myocardial infarctions or acute coronary syndromes
Known to suffer from stable angina pectoris and/or proven coronary disease, or have symptoms suspicious of coronary disease
